Prolacta Bioscience supports Breastfeeding Awareness Month with donation of breast pumps to Alliance for Black NICU Families
Type: Press Releases
Topic(s): Company Parents
Prolacta Bioscience congratulates Carolyn TenEyck, RN, on lifetime achievement award from National Black Nurses Association
Type: Press Releases
Topic(s): Advocacy Legislative
Enrollment completed in clinical trial evaluating effect of exclusive human milk diet including a specialty fortifier in term infants born with single ventricle physiology
Type: Press Releases
Topic(s): Single Ventricle Congenital Heart Defects (SVP )
Four studies showed Prolacta Bioscience’s 100% human milk-based fortifiers reduced retinopathy of prematurity (ROP) in premature infants
Type: Press Releases
Topic(s): Retinopathy of Prematurity (ROP)
Prolacta Bioscience provides update on latest SARS-CoV-2 data and continued safety of its human milk-based nutritional products
Type: Press Releases
Topic(s): Quality & Safety
Late-onset sepsis reduced in premature infants fed Prolacta’s 100% human milk-based fortifiers as part of an exclusive human milk diet
Type: Press Releases
Topic(s): Clinical Studies Clinical Studies on Prolact/Humavant CR Late-Onset Sepsis
Prolacta Bioscience fortifiers reduce risk of serious lung disease and hospital costs among premature infants, compared to cow milk-based fortifiers
Type: Press Releases
Topic(s): Bronchopulmonary Dysplasia (BPD)
NICU parents help other new parents through difficult times
Type: Parent Stories Press Releases
Topic(s): Parents
Research suggests some premature infants may go home from the NICU Up to 3 weeks earlier when fed Prolacta’s 100% human milk-based nutritional products; those with bronchopulmonary dysplasia may benefit the most
Type: Press Releases
Topic(s): Bronchopulmonary Dysplasia (BPD) Length of hospital stay